Von Hippel Lindau Vhl Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for von hippel lindau vhl disease. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
3
Active US patents
64/100
Avg vulnerability
$509M
Annual revenue covered

Originators in Von Hippel Lindau Vhl Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating von hippel lindau vhl disease. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Welireg
BELZUTIFAN
 Merck & Co. 3 64 $509M 2034-09-05

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
RE49948 Welireg method of use 75 2034-09-05
9908845 Welireg method of use 62 2034-09-05
12358870 Welireg formulation 55 2042-06-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12358870 Welireg formulation 55 2042-06-30
9908845 Welireg method of use 62 2034-09-05
RE49948 Welireg method of use 75 2034-09-05

Related